tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

DNTH Stock Latest News

Dianthus price target raised to $200 from $100 at Guggenheim
The FlyDianthus price target raised to $200 from $100 at Guggenheim
5h ago
DNTH
Dianthus price target raised to $200 from $100 at Guggenheim
PremiumThe Fly
Dianthus price target raised to $200 from $100 at Guggenheim
5h ago
DNTH
Dianthus Therapeutics: Best-in-Class Complement Inhibitor Potential and Multiple 2026 Catalysts Support Buy Rating
PremiumRatings
Dianthus Therapeutics: Best-in-Class Complement Inhibitor Potential and Multiple 2026 Catalysts Support Buy Rating
15d ago
DNTH
Dianthus Therapeutics: Multi-Indication Potential for Claseprubart Underpins Buy Rating Ahead of Key Phase II Readouts
PremiumRatings
Dianthus Therapeutics: Multi-Indication Potential for Claseprubart Underpins Buy Rating Ahead of Key Phase II Readouts
17d ago
DNTH
Dianthus participates in a conference call with William Blair
PremiumThe Fly
Dianthus participates in a conference call with William Blair
23d ago
DNTH
Pipeline-in-a-Product Momentum: De-Risked Autoimmune Neurology Catalyst Path Justifies Buy Rating on Claseprubart Franchise
PremiumRatingsPipeline-in-a-Product Momentum: De-Risked Autoimmune Neurology Catalyst Path Justifies Buy Rating on Claseprubart Franchise
1M ago
DNTH
Dianthus price target raised to $125 from $62 at Oppenheimer
Premium
The Fly
Dianthus price target raised to $125 from $62 at Oppenheimer
1M ago
DNTH
Dianthus files $600M mixed securities shelf
Premium
The Fly
Dianthus files $600M mixed securities shelf
1M ago
DNTH
Dianthus Therapeutics: Clinical Momentum, Pipeline Expansion, and Undervalued Catalysts Support Buy Rating
PremiumRatings
Dianthus Therapeutics: Clinical Momentum, Pipeline Expansion, and Undervalued Catalysts Support Buy Rating
2M ago
DNTH
Dianthus price target raised to $63 from $56 at Truist
PremiumThe Fly
Dianthus price target raised to $63 from $56 at Truist
2M ago
DNTH
Dianthus, Nanjing Leads Biolabs initiate Phase 1 trial of LBL-047
PremiumThe Fly
Dianthus, Nanjing Leads Biolabs initiate Phase 1 trial of LBL-047
2M ago
DNTH
Dianthus price target raised to $47 from $40 at H.C. Wainwright
PremiumThe Fly
Dianthus price target raised to $47 from $40 at H.C. Wainwright
4M ago
DNTH
Dianthus Therapeutics: Strong Financials and Promising Clinical Developments Justify Buy Rating
PremiumRatingsDianthus Therapeutics: Strong Financials and Promising Clinical Developments Justify Buy Rating
4M ago
DNTH
Dianthus price target raised to $62 from $60 at Oppenheimer
Premium
The Fly
Dianthus price target raised to $62 from $60 at Oppenheimer
4M ago
SNY
DNTH
Dianthus Therapeutics Reports Q3 2025 Financial Results
Premium
Company Announcements
Dianthus Therapeutics Reports Q3 2025 Financial Results
4M ago
DNTH
Dianthus Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating
PremiumRatings
Dianthus Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating
4M ago
DNTH
Dianthus reports Q3 EPS (97c), consensus (90c)
PremiumThe Fly
Dianthus reports Q3 EPS (97c), consensus (90c)
4M ago
DNTH
Dianthus Therapeutics Reports Positive Phase 2 Results
PremiumCompany Announcements
Dianthus Therapeutics Reports Positive Phase 2 Results
4M ago
8K
DNTH
Promising Clinical Data and Strategic Plans Position Dianthus Therapeutics as an Attractive Investment Opportunity
PremiumRatings
Promising Clinical Data and Strategic Plans Position Dianthus Therapeutics as an Attractive Investment Opportunity
4M ago
DNTH
Dianthus Therapeutics Advances CIDP Treatment with DNTH103 Study
PremiumCompany AnnouncementsDianthus Therapeutics Advances CIDP Treatment with DNTH103 Study
4M ago
DNTH
Dianthus Therapeutics Advances Phase 2 Study of DNTH103 for Neuropathy
Premium
Company Announcements
Dianthus Therapeutics Advances Phase 2 Study of DNTH103 for Neuropathy
4M ago
DNTH
Dianthus Therapeutics: Strategic Positioning and Innovative Pipeline Justify Buy Rating
Premium
Ratings
Dianthus Therapeutics: Strategic Positioning and Innovative Pipeline Justify Buy Rating
5M ago
DNTH

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >